Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor

Next Previous
Trial Profile

A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dorocubicel (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies
  • Focus Adverse reactions; First in man

Most Recent Events

  • 12 Dec 2022 According to a ExCellThera media release, results from retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants were presented in an oral session during the 2022 American Society of Hematology (ASH) Annual Meeting (Abstract #665).
  • 12 Dec 2022 Findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants published in the ExCellThera Media Release.
  • 04 Nov 2022 According to an ExCellThera media release, findings of a matched-controlled real-world analysis comparing outcomes of patients treated with ECT-001 in this trial to cord blood and matched unrelated donor peripheral blood stem cell transplants control cohorts identified from the CIBMTR (Center for International Blood and Marrow Transplant Research) research database has been accepted for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top